It did not take long for predictions of higher-priced merger-and-acquisition activity in 2025 to come true as Johnson & Johnson’s proposed $14.6bn buyout of Intra-Cellular and its rising neuropsychiatric drug Caplyta (lumateperone) was the largest of multiple billion-dollar plus transactions unveiled on 13 January.
J&J To Buy Intra-Cellular, Psychiatric Drug Caplyta For $14.6bn
Deal May Launch Anticipated Year Of Larger M&A
Johnson & Johnson started the M&A year with a bang at the J.P. Morgan meeting, unveiling its $14.6bn bid for Intra-Cellular. The deal would bolster its neuroscience portfolio and pipeline.
More from Deals
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus